LTRN: Reviving Failed Oncology Drugs with AI
By John Vandermosten, CFA NASDAQ:LTRN READ THE FULL LTRN RESEARCH REPORT Initiating Coverage We are initiating coverage of Lantern Pharma Inc., (NASDAQ:LTRN) with a current valuation of $28 per share. Lantern is a new type of drug development company employing artificial intelligence and big data to identify critical biomarkers and relevant indications for previously investigated […]
Continue reading